Cargando…

Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a

INTRODUCTION: Rare cases of thrombotic microangiopathy (TMA), manifested as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS), have been reported with interferon β products. We performed a cumulative review of TMA cases recorded in a Global Safety Database for patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben-Amor, Ali-Frédéric, Trochanov, Anton, Fischer, Tanya Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449386/
https://www.ncbi.nlm.nih.gov/pubmed/25991578
http://dx.doi.org/10.1007/s12325-015-0212-6
_version_ 1782373844613332992
author Ben-Amor, Ali-Frédéric
Trochanov, Anton
Fischer, Tanya Z.
author_facet Ben-Amor, Ali-Frédéric
Trochanov, Anton
Fischer, Tanya Z.
author_sort Ben-Amor, Ali-Frédéric
collection PubMed
description INTRODUCTION: Rare cases of thrombotic microangiopathy (TMA), manifested as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS), have been reported with interferon β products. We performed a cumulative review of TMA cases recorded in a Global Safety Database for patients with multiple sclerosis who received subcutaneous interferon β-1a treatment. METHODS: Search criteria were: all reported cases, serious and non-serious, from all sources (including non-health care professionals and clinical trial reports), regardless of event ranking and causality assessment by reporter or company. Data lock was May 3, 2014, with additional analysis of cases reported between August 1, 2014–November 30, 2014. RESULTS: Ninety-one patient cases (76.9% female) with 105 events were retrieved. Time to onset varied from 2 months to 14 years, and in 31.9% of patients the event occurred within 2 years of treatment initiation. Seven patients had a fatal outcome (five were secondary to other causes and two reported insufficient information). Forty-four patients recovered, 32 patients had not recovered at the time of the report, and in eight cases outcome was either not reported or unknown. Treatment was discontinued in 84.6% (77/91) of patients. In 67% (61/91) of patients, the reporter suspected a causal association between treatment and TMA/TTP-HUS. Risk factors and/or confounding factors were present in 45.1% (41/91) of patients. Early prodromal syndrome or specific patterns were not detected, although 54.9% (50/91) of cases contained insufficient information. Overall reporting rate of TMA/TTP-HUS was estimated as 7.2 per 100,000 patient-years. Reporting rates for human serum album (HSA)-containing and HSA-free formulations were 5.72 and 7.68 per 100,000 patient-years, respectively. CONCLUSION: No new signal relating specifically to increased frequency of TMA/TTP-HUS with HSA-free subcutaneous interferon β-1a was detected and no additional risk mitigation measures are required regarding the different formulations. The benefit–risk balance of subcutaneous interferon β-1a remains positive, and routine pharmacovigilance monitoring is appropriate. FUNDING: Ares Trading SA, Aubonne, Switzerland, a subsidiary of Merck Serono SA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-015-0212-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4449386
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-44493862015-06-04 Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a Ben-Amor, Ali-Frédéric Trochanov, Anton Fischer, Tanya Z. Adv Ther Original Research INTRODUCTION: Rare cases of thrombotic microangiopathy (TMA), manifested as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS), have been reported with interferon β products. We performed a cumulative review of TMA cases recorded in a Global Safety Database for patients with multiple sclerosis who received subcutaneous interferon β-1a treatment. METHODS: Search criteria were: all reported cases, serious and non-serious, from all sources (including non-health care professionals and clinical trial reports), regardless of event ranking and causality assessment by reporter or company. Data lock was May 3, 2014, with additional analysis of cases reported between August 1, 2014–November 30, 2014. RESULTS: Ninety-one patient cases (76.9% female) with 105 events were retrieved. Time to onset varied from 2 months to 14 years, and in 31.9% of patients the event occurred within 2 years of treatment initiation. Seven patients had a fatal outcome (five were secondary to other causes and two reported insufficient information). Forty-four patients recovered, 32 patients had not recovered at the time of the report, and in eight cases outcome was either not reported or unknown. Treatment was discontinued in 84.6% (77/91) of patients. In 67% (61/91) of patients, the reporter suspected a causal association between treatment and TMA/TTP-HUS. Risk factors and/or confounding factors were present in 45.1% (41/91) of patients. Early prodromal syndrome or specific patterns were not detected, although 54.9% (50/91) of cases contained insufficient information. Overall reporting rate of TMA/TTP-HUS was estimated as 7.2 per 100,000 patient-years. Reporting rates for human serum album (HSA)-containing and HSA-free formulations were 5.72 and 7.68 per 100,000 patient-years, respectively. CONCLUSION: No new signal relating specifically to increased frequency of TMA/TTP-HUS with HSA-free subcutaneous interferon β-1a was detected and no additional risk mitigation measures are required regarding the different formulations. The benefit–risk balance of subcutaneous interferon β-1a remains positive, and routine pharmacovigilance monitoring is appropriate. FUNDING: Ares Trading SA, Aubonne, Switzerland, a subsidiary of Merck Serono SA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-015-0212-6) contains supplementary material, which is available to authorized users. Springer Healthcare 2015-05-20 2015 /pmc/articles/PMC4449386/ /pubmed/25991578 http://dx.doi.org/10.1007/s12325-015-0212-6 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Ben-Amor, Ali-Frédéric
Trochanov, Anton
Fischer, Tanya Z.
Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a
title Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a
title_full Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a
title_fullStr Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a
title_full_unstemmed Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a
title_short Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a
title_sort cumulative review of thrombotic microangiopathy, thrombotic thrombocytopenic purpura, and hemolytic uremic syndrome reports with subcutaneous interferon β-1a
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449386/
https://www.ncbi.nlm.nih.gov/pubmed/25991578
http://dx.doi.org/10.1007/s12325-015-0212-6
work_keys_str_mv AT benamoralifrederic cumulativereviewofthromboticmicroangiopathythromboticthrombocytopenicpurpuraandhemolyticuremicsyndromereportswithsubcutaneousinterferonb1a
AT trochanovanton cumulativereviewofthromboticmicroangiopathythromboticthrombocytopenicpurpuraandhemolyticuremicsyndromereportswithsubcutaneousinterferonb1a
AT fischertanyaz cumulativereviewofthromboticmicroangiopathythromboticthrombocytopenicpurpuraandhemolyticuremicsyndromereportswithsubcutaneousinterferonb1a